Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 135,619 |
|
|||||
| News | - | ||||||
| Day High | 14.32 | Low High |
|||||
| Day Low | 13.69 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| UroGen Pharma Ltd | URGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.33 | 2.39% | 14.15 | 16:25:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.97 | 13.69 | 14.32 | 14.15 | 13.82 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,145 | 135,619 | $ 14.03 | $ 1,902,847 | - | 8.69 - 24.13 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:45:15 | 50 | $ 14.42 | USD |
UroGen Pharma Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 483.17M | 34.12M | - | 82.71M | -102.24M | -3.00 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
UroGen Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical URGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.06 | 14.85 | 13.17 | 14.09 | 233,436 | 0.09 | 0.64% |
| 1 Month | 14.75 | 15.50 | 12.37 | 14.26 | 306,110 | -0.60 | -4.07% |
| 3 Months | 15.75 | 19.87 | 12.37 | 16.22 | 370,601 | -1.60 | -10.16% |
| 6 Months | 11.29 | 19.87 | 10.63 | 15.16 | 316,602 | 2.86 | 25.33% |
| 1 Year | 11.62 | 24.13 | 8.69 | 16.13 | 379,823 | 2.53 | 21.77% |
| 3 Years | 19.61 | 24.13 | 4.85 | 14.05 | 205,718 | -5.46 | -27.84% |
| 5 Years | 37.03 | 39.97 | 4.85 | 18.55 | 199,418 | -22.88 | -61.79% |
UroGen Pharma Description
| UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. |
